IM Cannabis Raises US$2.17 Million via Convertible Notes to Bolster Liquidity

The latest update is out from IM Cannabis Corp ( (IMCC) ).

On January 26, 2026, IM Cannabis Corp. announced it had raised US$2,171,660.40 in debt financings from an arm’s length institutional lender through two convertible note purchase agreements dated January 7 and January 20, 2026. The first note, issued at a discounted principal of US$1,538,749, and the second note, at US$632,911.50, both carry 8% annual interest (rising to 14% on default), 18‑month maturities with optional extensions, and are convertible into common shares at the lower of fixed prices (US$1.47 and US$1.38, respectively) or a 10% discount to the 20‑day VWAP, subject to floor prices of US$0.29 and US$0.275. In connection with the financings, IMC issued the lender a total of 321,821 common share purchase warrants exercisable at C$3.45 for five years, with all securities subject to a four‑month hold, and committed to register the resale of the underlying shares with the U.S. SEC. Roughly US$1 million of the proceeds were applied to repay existing creditors and the balance earmarked for working capital and corporate initiatives, a move that reduces short‑term liabilities, addresses immediate liquidity needs and, while potentially dilutive over time due to conversion features, provides the cash flexibility IMC needs to support operations in its core Israeli and German medical cannabis markets.

The most recent analyst rating on (IMCC) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on IM Cannabis Corp stock, see the IMCC Stock Forecast page.

Spark’s Take on IMCC Stock

According to Spark, TipRanks’ AI Analyst, IMCC is a Underperform.

The score is driven primarily by weak financial performance—ongoing losses, high leverage relative to equity, and continued cash burn. Technical signals also lean bearish with price below major moving averages and negative MACD, while valuation is difficult to support given a negative P/E and no dividend.

To see Spark’s full report on IMCC stock, click here.

More about IM Cannabis Corp

IM Cannabis Corp. (IMC) is an international medical cannabis company listed on Nasdaq that supplies premium cannabis products to medical patients in Israel and Germany. The group operates a transnational, data-driven ecosystem spanning import, distribution, retail pharmacies and online platforms in Israel, and pharmaceutical distribution through Adjupharm GmbH in Germany, with a strategic focus on sustainable, profitable growth in these high-value, tightly regulated markets.

Average Trading Volume: 178,265

Technical Sentiment Signal: Sell

Current Market Cap: $7.08M

For a thorough assessment of IMCC stock, go to TipRanks’ Stock Analysis page.